Acute agitation and aggression treatment market seen reaching $8.37 billion by 2030
The Business Research Company says the acute agitation and aggression treatment market is on track to grow from $6.05 billion in 2025 to $8.37 billion by 2030. Rising dementia cases, faster-acting therapies and broader behavioral health care adoption are among the main forces shaping the outlook.
Why it matters: - Acute agitation and aggression treatment is tied to emergency care, psychiatric care and dementia management. - The market’s growth signals stronger demand for fast-acting therapies and integrated behavioral health models. - Rising dementia prevalence adds to the number of patients who may need treatment for agitation and aggression.
What happened: - The Business Research Company released a report on the global acute agitation and aggression treatment market on Oct. 28, 2026. - The market is projected to rise from $6.05 billion in 2025 to $6.36 billion in 2026. - The report projects the market will reach $8.37 billion by 2030. - The report places the market’s 2025-2026 CAGR at 5.2% and the 2026-2030 CAGR at 7.1%. - A free sample of the report is available here. - The full report is available here.
The details: - The report defines acute agitation and aggression treatment as medical and therapeutic efforts to control sudden episodes of restlessness, irritability and aggressive behavior. - The report says these episodes can stem from psychiatric or neurological disorders, or from substance use or withdrawal. - Historical growth has been driven by rising psychiatric disorders, more emergency department visits for agitation cases, broader access to antipsychotic medications, growth in mental health services and greater public awareness of behavioral health conditions. - The report points to rising demand for fast-acting therapeutic treatments, more investment in neuropsychiatric drug development, wider use of digital mental health tools, broader integrated behavioral care models and a stronger focus on patient-centered treatment approaches. - Forecast-period trends include rapid-acting pharmacologic therapies, personalized psychiatry practices, digital monitoring technologies, enhanced emergency behavioral care protocols and a greater emphasis on patient safety. - The report says effective management helps improve patient outcomes and reduce risks linked to aggression.
Between the lines: - Dementia is a major growth driver because agitation is common in patients with cognitive decline. - The report cites Australian Institute of Health and Welfare data showing about 401,300 Australians were living with dementia in 2022. - That figure is projected to nearly double to 849,300 by 2058. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth through the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.
What's next: - The market’s growth path will depend on uptake of rapid-acting treatments and continued expansion in behavioral health care delivery. - Wider use of digital tools and integrated care models may shape how agitation episodes are identified and treated. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics and updated trend analysis.
The bottom line: - Demand for faster, more targeted agitation treatments is rising as dementia cases and behavioral health needs grow worldwide.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Australia Post Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.